Q-Pharm Pty Ltd
Welcome,         Profile    Billing    Logout  
 5 Trials 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McCarthy, James J
EBS-UFV-001, NCT05155319: Universal Influenza A Vaccine in Healthy Adults

Completed
1
27
RoW
UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo
Emergent BioSolutions
Human Influenza
10/23
10/23
HD-MAP, NCT06417853: Influenza a (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch

Active, not recruiting
1
267
RoW
Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant), Microarray Patch Delivery System
Vaxxas Pty Ltd, Biomedical Advanced Research and Development Authority
H7N9 Influenza
05/26
05/26
iGP3-SWITCH, NCT06881732: Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite with the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP

Not yet recruiting
1
2
RoW
NF54/iGP3
University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Swiss Tropical & Public Health Institute, QIMR Berghofer Medical Research Institute
Malaria Falciparum, Malaria Infection, Malaria Transmission
07/26
07/26
HRN, NCT06057181: Helix Research Network

Recruiting
N/A
2000000
US
Exome sequencing
Helix, Inc, Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Nebraska Medicine - University of Nebraska Medical Center, Sanford Health, Cone Health, Renown Health, WakeMed Health & Hospitals, The Ohio State University Wexner Medical Center
Genetic Predisposition to Disease, Genetics Disease
09/31
09/36
Wong, Elaine K
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
NCT04921254: A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.

Recruiting
1
72
RoW
BSG005 or placebo, BSG005, Placebo
Biosergen AS, Select Pharma Pty Ltd, Greenlight Clinical, Nucleus Network Ltd
Invasive Fungal Infections
03/23
05/23
McLendon, Kristi
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
02/25
02/26
CTP-00070-00, NCT05152901: Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

Completed
1
23
RoW
EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg), Epinephrine (4mg)
De Motu Cordis, Novotech (Australia) Pty Limited
Anaphylactic Reaction
06/22
06/22
NCT05340790: First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories

Recruiting
1
50
RoW
Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, AMP PL-18, Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, Placebo PL-18
Protelight Pharmaceuticals Australia PTY LTD
Colpomycosis, Bacterial Vaginosis, Mixede Vaginitis
12/23
03/24
NCT05775887: A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

Completed
1
70
RoW
UQSC2 Vaccine, NVX-CoV2373 vaccine
The University of Queensland, Coalition for Epidemic Preparedness Innovations
COVID-19
12/23
12/23
NCT05805618: Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

Not yet recruiting
1
60
NA
Recombinant Norovirus Hexavalent Vaccine, KH002, Matching Placebo
Syneos Health, Chengdu Kanghua Biological products Co., Ltd.
Gastroenteritis
11/24
11/24
NCT05799651: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults

Active, not recruiting
1
36
RoW
Glycovax-002
Glycovax Pharma Inc., Government of Canada, JSS Medical Research Inc., Avance Clinical Pty Ltd., Seppic
SARS-CoV-2
06/24
12/24
NCT05053334: Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

Completed
1
165
RoW
Omalizumab Prefilled Syringe
Syneos Health, CuraTeQ Biologics Private Ltd.
Healthy Volunteers
11/23
11/23
NCT05555758: Aom0319 SAD Study in Healthy Subjects

Completed
1
38
RoW
Adamgammadex Sodium, Aom0319, 0.9% Sodium Chloride Injection, Placebo
Amckaus PTY LTD.
Healthy Volunteers
12/23
12/23
NCT06019065: A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects

Completed
1
64
RoW
AJA001, Placebo
AJNA Australia Pty Ltd
Healthy Volunteers
03/24
05/24
NCT05491421: A Study of ZT002 in Healthy Participants

Recruiting
1
56
RoW
ZT002, Placebo
QL Biopharmaceutical Australia Pty Ltd, Novotech (Australia) Pty Limited, Beijing QL Biopharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus
12/23
04/24
NCT06125691: Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Active, not recruiting
1
135
RoW
ARCT-2138, Self-Amplifying RNA seasonal Influenza vaccine, Licensed Quadrivalent Vaccine for younger adults, Influenza vaccine, surface antigen, inactivated, prepared in cell cultures, Licensed Quadrivalent Vaccine for older adults, Influenza vaccine, surface antigen, inactivated, adjuvanted
Arcturus Therapeutics, Inc., Seqirus, Novotech (Australia) Pty Limited
Influenza, Human
09/24
01/25
NCT05905068: Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

Completed
1
32
RoW
RN0191 INJECTION
Ikaria Bioscience Pty Ltd
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities
02/24
05/24
NCT06028347: Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

Completed
1
96
RoW
sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3, Placebo
Seqirus
Influenza, Human
10/24
10/24
NCT05896969: Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Completed
1
41
RoW
SNK-396 - SAD cohort, SNK-396 - MAD Cohort
Syneos Health, SynerK Pharmatech (Suzhou) Limited
Elevated Low-Density Lipoprotein Cholesterol
02/24
02/24
Friend, Richard
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed
1/2
75
RoW
LASN01, Placebo
Lassen Therapeutics 1 PTY LTD
Pulmonary Fibrosis, Thyroid Eye Disease
11/24
11/24
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients

Recruiting
1/2
50
Europe, RoW
ADX-038, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited
Paroxysmal Nocturnal Hemoglobinuria (PNH)
03/26
09/26
ACTRN12621001077853p: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women

Not yet recruiting
1
80
 
Keros Therapeutics, Keros Therapeutics
Healthy Postmenopausal Women
 
 
ACTRN12620000013965: A Study to Compare the Pharmacokinetic Similarity of JHL1266 versus Prolia in Healthy Subjects

Not yet recruiting
1
225
 
JHL Biotech Australia Pty Ltd., JHL Biotech Australia Pty Ltd.
Osteoporosis
 
 
ACTRN12622000293763: A study comparing extended release and immediate release formulations of EQ121 in adult healthy volunteers of Chinese descent- Part C

Withdrawn
1
10
 
EQRx International, Inc., EQRx International, Inc.
Rheumatoid Arthritis
 
 
ACTRN12621000103864: To assess the safety, tolerability and pharmacokinetics of INCB86550 in healthy adult population.

Completed
1
75
 
Incyte Corporation, Incyte Corporation
Cancer
 
 
ACTRN12621001216808: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of EQ121 following oral single (Part 1) and multiple (Part 2) ascending dose administration in healthy subjects.

Active, not recruiting
1
104
 
EQRx, Inc, EQRx, Inc
Rheumatoid Arthritis
 
 
ACTRN12621001077853: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women

Completed
1
80
 
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Healthy Postmenopausal Women
 
 
ACTRN12621000514808: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of mEphA4-Fc

Completed
1
28
 
NuNerve Pty. Ltd., NuNerve Pty. Ltd.
Amyotrophic Lateral Sclerosis
 
 
ACTRN12622000292774: A study comparing extended release and immediate release formulations of EQ121 in healthy adult volunteers- Part B

Completed
1
12
 
EQRx International, Inc., EQRx International, Inc.
Rheumatoid Arthritis
 
 
ACTRN12622000307707: A study comparing extended release and immediate release formulations of EQ121 following single doses in healthy adult volunteers- Part A

Completed
1
40
 
EQRx International, Inc., EQRx International, Inc.
Rheumatoid Arthritis
 
 
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
NCT05174013: Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Completed
1
32
RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
06/23
06/23
ACTRN12621001571864: First-in-Human Study of RLYB116 in Healthy Participants

Completed
1
88
 
IPC Research, LLC, IPC Research, LLC
complement mediated diseases
 
 
NCT05225857: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Completed
1
90
RoW
AGA2118, Placebo
Angitia Biopharmaceuticals, Angitia Australia Pty Ltd
Osteoporosis
01/24
01/24
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Completed
1
31
RoW
TNB-738
TeneoFour Inc., Novotech (Australia) Pty Limited
Healthy Volunteer
05/23
07/23
AT02-001, NCT05521022: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Recruiting
1
100
US, RoW
AT-02, AT-02 (Placebo)
Attralus, Inc., Novotech (Australia) Pty Limited
Amyloidosis; Systemic
03/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McCarthy, James J
EBS-UFV-001, NCT05155319: Universal Influenza A Vaccine in Healthy Adults

Completed
1
27
RoW
UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo
Emergent BioSolutions
Human Influenza
10/23
10/23
HD-MAP, NCT06417853: Influenza a (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch

Active, not recruiting
1
267
RoW
Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant), Microarray Patch Delivery System
Vaxxas Pty Ltd, Biomedical Advanced Research and Development Authority
H7N9 Influenza
05/26
05/26
iGP3-SWITCH, NCT06881732: Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite with the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP

Not yet recruiting
1
2
RoW
NF54/iGP3
University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Swiss Tropical & Public Health Institute, QIMR Berghofer Medical Research Institute
Malaria Falciparum, Malaria Infection, Malaria Transmission
07/26
07/26
HRN, NCT06057181: Helix Research Network

Recruiting
N/A
2000000
US
Exome sequencing
Helix, Inc, Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Nebraska Medicine - University of Nebraska Medical Center, Sanford Health, Cone Health, Renown Health, WakeMed Health & Hospitals, The Ohio State University Wexner Medical Center
Genetic Predisposition to Disease, Genetics Disease
09/31
09/36
Wong, Elaine K
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
NCT04921254: A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.

Recruiting
1
72
RoW
BSG005 or placebo, BSG005, Placebo
Biosergen AS, Select Pharma Pty Ltd, Greenlight Clinical, Nucleus Network Ltd
Invasive Fungal Infections
03/23
05/23
McLendon, Kristi
NCT06291857: A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

Not yet recruiting
3
9320
RoW
CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, COVID-19 and influenza combination, Novavax COVID-19 Vaccine, Novavax SARS-CoV-2 rS vaccine, tNIV Vaccine, Trivalent Nanoparticle Influenza Hemagglutinin Vaccine, Fluzone High Dose, Fluzone HD
Novavax
COVID-19
02/25
02/26
CTP-00070-00, NCT05152901: Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults

Completed
1
23
RoW
EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg), Epinephrine (4mg)
De Motu Cordis, Novotech (Australia) Pty Limited
Anaphylactic Reaction
06/22
06/22
NCT05340790: First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories

Recruiting
1
50
RoW
Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, AMP PL-18, Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, Placebo PL-18
Protelight Pharmaceuticals Australia PTY LTD
Colpomycosis, Bacterial Vaginosis, Mixede Vaginitis
12/23
03/24
NCT05775887: A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

Completed
1
70
RoW
UQSC2 Vaccine, NVX-CoV2373 vaccine
The University of Queensland, Coalition for Epidemic Preparedness Innovations
COVID-19
12/23
12/23
NCT05805618: Evaluation of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects

Not yet recruiting
1
60
NA
Recombinant Norovirus Hexavalent Vaccine, KH002, Matching Placebo
Syneos Health, Chengdu Kanghua Biological products Co., Ltd.
Gastroenteritis
11/24
11/24
NCT05799651: Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults

Active, not recruiting
1
36
RoW
Glycovax-002
Glycovax Pharma Inc., Government of Canada, JSS Medical Research Inc., Avance Clinical Pty Ltd., Seppic
SARS-CoV-2
06/24
12/24
NCT05053334: Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

Completed
1
165
RoW
Omalizumab Prefilled Syringe
Syneos Health, CuraTeQ Biologics Private Ltd.
Healthy Volunteers
11/23
11/23
NCT05555758: Aom0319 SAD Study in Healthy Subjects

Completed
1
38
RoW
Adamgammadex Sodium, Aom0319, 0.9% Sodium Chloride Injection, Placebo
Amckaus PTY LTD.
Healthy Volunteers
12/23
12/23
NCT06019065: A SAD, MAD and Food Effect Study to Evaluate the Safety, Tolerability, PK, and PD of AJA001 in Healthy Subjects

Completed
1
64
RoW
AJA001, Placebo
AJNA Australia Pty Ltd
Healthy Volunteers
03/24
05/24
NCT05491421: A Study of ZT002 in Healthy Participants

Recruiting
1
56
RoW
ZT002, Placebo
QL Biopharmaceutical Australia Pty Ltd, Novotech (Australia) Pty Limited, Beijing QL Biopharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus
12/23
04/24
NCT06125691: Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Active, not recruiting
1
135
RoW
ARCT-2138, Self-Amplifying RNA seasonal Influenza vaccine, Licensed Quadrivalent Vaccine for younger adults, Influenza vaccine, surface antigen, inactivated, prepared in cell cultures, Licensed Quadrivalent Vaccine for older adults, Influenza vaccine, surface antigen, inactivated, adjuvanted
Arcturus Therapeutics, Inc., Seqirus, Novotech (Australia) Pty Limited
Influenza, Human
09/24
01/25
NCT05905068: Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

Completed
1
32
RoW
RN0191 INJECTION
Ikaria Bioscience Pty Ltd
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other Comorbidities
02/24
05/24
NCT06028347: Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

Completed
1
96
RoW
sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3, Placebo
Seqirus
Influenza, Human
10/24
10/24
NCT05896969: Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

Completed
1
41
RoW
SNK-396 - SAD cohort, SNK-396 - MAD Cohort
Syneos Health, SynerK Pharmatech (Suzhou) Limited
Elevated Low-Density Lipoprotein Cholesterol
02/24
02/24
Friend, Richard
NCT05331300: A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease

Completed
1/2
75
RoW
LASN01, Placebo
Lassen Therapeutics 1 PTY LTD
Pulmonary Fibrosis, Thyroid Eye Disease
11/24
11/24
PNH, NCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria () Patients

Recruiting
1/2
50
Europe, RoW
ADX-038, siRNA, Placebo, Saline
ADARx Pharmaceuticals, Inc., ADARx Australia Pty Ltd, Novotech (Australia) Pty Limited
Paroxysmal Nocturnal Hemoglobinuria (PNH)
03/26
09/26
ACTRN12621001077853p: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women

Not yet recruiting
1
80
 
Keros Therapeutics, Keros Therapeutics
Healthy Postmenopausal Women
 
 
ACTRN12620000013965: A Study to Compare the Pharmacokinetic Similarity of JHL1266 versus Prolia in Healthy Subjects

Not yet recruiting
1
225
 
JHL Biotech Australia Pty Ltd., JHL Biotech Australia Pty Ltd.
Osteoporosis
 
 
ACTRN12622000293763: A study comparing extended release and immediate release formulations of EQ121 in adult healthy volunteers of Chinese descent- Part C

Withdrawn
1
10
 
EQRx International, Inc., EQRx International, Inc.
Rheumatoid Arthritis
 
 
ACTRN12621000103864: To assess the safety, tolerability and pharmacokinetics of INCB86550 in healthy adult population.

Completed
1
75
 
Incyte Corporation, Incyte Corporation
Cancer
 
 
ACTRN12621001216808: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of EQ121 following oral single (Part 1) and multiple (Part 2) ascending dose administration in healthy subjects.

Active, not recruiting
1
104
 
EQRx, Inc, EQRx, Inc
Rheumatoid Arthritis
 
 
ACTRN12621001077853: A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women

Completed
1
80
 
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Healthy Postmenopausal Women
 
 
ACTRN12621000514808: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of mEphA4-Fc

Completed
1
28
 
NuNerve Pty. Ltd., NuNerve Pty. Ltd.
Amyotrophic Lateral Sclerosis
 
 
ACTRN12622000292774: A study comparing extended release and immediate release formulations of EQ121 in healthy adult volunteers- Part B

Completed
1
12
 
EQRx International, Inc., EQRx International, Inc.
Rheumatoid Arthritis
 
 
ACTRN12622000307707: A study comparing extended release and immediate release formulations of EQ121 following single doses in healthy adult volunteers- Part A

Completed
1
40
 
EQRx International, Inc., EQRx International, Inc.
Rheumatoid Arthritis
 
 
NCT05184322: XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Recruiting
1
90
RoW
T2026, Absorption enhancer excipient, Placebo, Oral ecnoglutide tablet, GLP-1 analogue, XW004
Sciwind Biosciences APAC CO Pty. Ltd., Hangzhou Sciwind Biosciences Co., Ltd., Sciwind Biosciences USA Co., Ltd.
Obesity, Type 2 Diabetes Mellitus
07/24
08/24
NCT05174013: Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Completed
1
32
RoW
GSK3858279, Placebo
GlaxoSmithKline
Pain
06/23
06/23
ACTRN12621001571864: First-in-Human Study of RLYB116 in Healthy Participants

Completed
1
88
 
IPC Research, LLC, IPC Research, LLC
complement mediated diseases
 
 
NCT05225857: A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Completed
1
90
RoW
AGA2118, Placebo
Angitia Biopharmaceuticals, Angitia Australia Pty Ltd
Osteoporosis
01/24
01/24
NCT05215912: A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Completed
1
31
RoW
TNB-738
TeneoFour Inc., Novotech (Australia) Pty Limited
Healthy Volunteer
05/23
07/23
AT02-001, NCT05521022: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Recruiting
1
100
US, RoW
AT-02, AT-02 (Placebo)
Attralus, Inc., Novotech (Australia) Pty Limited
Amyloidosis; Systemic
03/25
03/25

Download Options